EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials

Sining Xie iD, Federica Galimberti iD, Elena Olmastroni iD, Thomas F Luscher, Stefano Carugo iD, Alberico L Catapano iD, Manuela Casula iD, META-LIPID Group

Cardiovascular Research · 30.03.2024 · 120 (4) · 333-344

DOI: 10.1093/cvr/cvae034 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cardiovascular Research, online erschienen am 19.02.2024. Verfasst von Sining Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzarett…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anticholesteremic Agents, Cardiovascular Diseases, Atherosclerosis. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of Health-IRCCS MultiMedica, Italian Ministry of Health-Ricerca Corrente-IRCCS MultiMedica, Italian Ministry of Health—Ricerca Corrente—IRCCS MultiMedica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic low-degree inflammation is a hallmark of atherosclerotic cardiovascular (CV) disease. To assess the effect of lipid-lowering therapies on C-reactive protein (CRP), a biomarker of inflammation, we conducted a meta-analysis according to the PRISMA guidelines. Databases were searched from inception to July 2023. Inclusion criteria were: (i) randomized controlled trials (RCTs) in human, Phase II, III, or IV; (ii) English language; (iii) comparing the effect of lipid-lowering drugs vs. placebo; (iv) reporting the effects on CRP levels; (v) with intervention duration of more than 3 weeks; (vi) and sample size (for both intervention and control group) over than 100 subjects. The between-group (treatment-placebo) CRP absolute mean differences and 95% confidence intervals were calculated for each drug class separately. A total of 171 668 subjects from 53 RCTs were included. CRP levels (mg/L) were significantly decreased by statins [−0.65 (−0.87 to −0.43), bempedoic acid; −0.43 (−0.67 to −0.20), ezetimibe; −0.28 (−0.48 to −0.08)], and omega-3 fatty acids [omega3FAs, −0.27 (−0.52 to −0.01)]. CRP was reduced by −0.40 (−1.17 to 0.38) with fibrates, although not statistically significant. A slight increase of CRP concentration was observed for proprotein convertase subtilisin/kexin type 9 inhibitors [0.11 (0.07–0.14)] and cholesteryl-ester transfer protein inhibitors [0.10 (0.00–0.21)], the latter being not statistically significant. Meta-regression analysis did not show a significant correlation between changes in CRP and LDL cholesterol (LDL-C) or triglycerides. Statins, bempedoic acid, ezetimibe, and omega3FAs significantly reduce serum CRP concentration, independently of LDL-C reductions. The impact of this anti-inflammatory effect in terms of CV prevention needs further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic AgentsCardiovascular DiseasesAtherosclerosisDicarboxylic AcidsFatty AcidsHumansCholesterol, LDLC-Reactive ProteinRandomized Controlled Trials as TopicEzetimibeInflammation

Stichwörter der Autor:innen

C-reactive proteinCardiovascular diseaseInflammationLipid-lowering therapies

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic Agents8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidCholesterol, LDLC-Reactive ProteinEzetimibeDicarboxylic AcidsFatty Acids

Autor:innen und Institutionen

  • Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20033 Milan, Italy.
  • IRCCS MultiMedica, via Milanese 300, 20099 Sesto San Giovanni (Milan), Italy.
  • Center for Molecular Cardiology, University Zurich, Wagistrasse 12, 8952 Schlieren (Zurich), Switzerland.
  • Cardiac Unit, Royal Brompton and Harefield Hospitals GSTT, Imperial College and King's College London, Sydney Street, SW3 6NP London, UK.
  • Department of Clinical Sciences and Community Health, University of Milan, via della Commenda 19, 20122 Milan, Italy.
  • Cardiology Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, via Francesco Sforza 28, 20122 Milan, Italy.

ORCID-Profile: Sining Xie, Federica Galimberti, Elena Olmastroni, Stefano Carugo, Alberico L Catapano, Manuela Casula

Förderung

  • Italian Ministry of Health-IRCCS MultiMedica
  • Italian Ministry of Health-Ricerca Corrente-IRCCS MultiMedica
  • Italian Ministry of Health—Ricerca Corrente—IRCCS MultiMedica

Zitieren

APA

Xie, S., Galimberti, F., Olmastroni, E., Luscher, T. F., Carugo, S., Catapano, A. L., Casula, M., & META-LIPID Group (2024). Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials. Cardiovascular Research, 120(4), 333-344. https://doi.org/10.1093/cvr/cvae034

Vancouver

Xie S, Galimberti F, Olmastroni E, Luscher TF, Carugo S, Catapano AL, et al. Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials. Cardiovascular Research. 2024;120(4):333-344. doi:10.1093/cvr/cvae034

BibTeX
@article{Xie2024,
  author = {Xie, Sining and Galimberti, Federica and Olmastroni, Elena and Luscher, Thomas F and Carugo, Stefano and Catapano, Alberico L and Casula, Manuela and META-LIPID Group, META-LIPID Group},
  title = {Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials},
  journal = {Cardiovascular Research},
  year = {2024},
  volume = {120},
  number = {4},
  pages = {333--344},
  doi = {10.1093/cvr/cvae034}
}
Kostenlos starten →